Effect of omalizumab on peripheral blood eosinophilia in allergic asthma  by Massanari, M. et al.
Respiratory Medicine (2010) 104, 188e196ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedEffect of omalizumab on peripheral blood
eosinophilia in allergic asthmaM. Massanari a,*, S.T. Holgate b, W.W. Busse c, P. Jimenez a,
F. Kianifard a, R. Zeldin aa Novartis Pharmaceuticals Corp., East Hanover, NJ 07936-1080, USA
b Southampton General Hospital, Southampton, UK
c University of Wisconsin, USA
Received 23 December 2008; accepted 17 September 2009
Available online 20 October 2009KEYWORDS
Omalizumab;
IgE;
Eosinophils;
Allergy;
Asthma* Corresponding author. Tel.: þ44 8
2802.
E-mail address: marc.massanari@n
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.09.011Summary
Eosinophilia is an established marker of asthma-related inflammation. We assessed the effect of
omalizumab on peripheral blood eosinophil counts using a pooled analysis of data from five
randomized, double-blind, placebo-controlled studies in patients with moderate-to-severe
persistent allergic asthma receivingmoderate-to-high-dose inhaled corticosteroids (omalizumab,
nZ 1136; placebo, nZ 1100). Relationships between omalizumab, peripheral blood eosinophils,
serum free IgE concentrations and clinical outcomes were explored. Baseline mean eosinophil
counts were similar in each treatment group. Post-treatment eosinophil counts were significantly
reduced from baseline in the omalizumab group (p< 0.0001) but were not significantly different
in the placebo group. Greater reductions in eosinophil counts were observed in patients who had
post-treatment free IgE levels <50 ng/mL. Three studies included steroid-stable and steroid-
reduction phases. At the end of each phase in these studies, a significantly greater reduction in
eosinophil counts was achieved in the omalizumab group compared with the placebo group
(p< 0.0001). A consistent pattern of improved clinical outcomes/decreased eosinophils and
worsened clinical outcomes/increased eosinophils was observed for both omalizumab and
placebo treatment groups. The findings from our analysis of a large patient population are consis-
tent with earlier reports of the inhibitory effect of omalizumab on eosinophils.
ª 2009 Elsevier Ltd. All rights reserved.62 778 7843. Mobile: 973 896
ovartis.com (M. Massanari).
9 Elsevier Ltd. All rights reservedIntroduction
Asthma is a chronic inflammatory disorder of the airways
that is often allergic in nature and characterized by the
presence of immunoglobulin E (IgE) antibodies against one
or more common environmental allergens.1e5 The main.
Table 1 Studies included in the pooled analysis.
Study Patient population Patients
(n)
Duration
(weeks)
Humbert
et al.10
Inadequately controlled
severe allergic asthma
despite GINA 2002 Step
4 therapy
419 28
Vignola
et al.11
Moderate-to-severe
allergic asthma and
rhinitis
405 28
Busse
et al.12
Severe allergic asthma 525 28a,b
Sole`r
et al.13
Moderate-to-severe
allergic asthma
546 28a,b
Holgate
et al.14
Severe allergic asthma
dependent on high-dose
ICS
341 32c
a 16-week steroid-stable phase followed by a 12-week steroid-
reduction phase.
b Additional 24-week extension phase.
c 16-week steroid-stable phase followed by a 16-week steroid-
reduction phase.
Effect of omalizumab on eosinophilia in allergic asthma 189phases of allergic asthma are: sensitization to an allergen,
an early asthmatic response (within minutes of allergen
exposure), a late asthmatic response (within hours/days of
allergen exposure), and airway remodelling.
The important role of eosinophils in inflammation is well
documented, and eosinophilia is established as a good
marker of inflammation in patients with asthma.3,6 Eosin-
ophils release a variety of pro-inflammatory mediators
including granule-stored cationic proteins, newly synthe-
sized eicosanoids and cytokines.3,6 Furthermore, sputum
eosinophil counts correlate closely with asthma severity7
and both the risk and severity of exacerbations.8,9
Anti-IgE therapy with omalizumab, added to medium- or
high-dose inhaled corticosteroids (ICS), with or without
a long-acting b2-agonist, has proven effective in the treat-
ment of patients with moderate-to-severe and severe
allergic (IgE-mediated) asthma by reducing exacerbations
and associated use of rescue bursts of systemic corticoster-
oids in addition to improving other clinical outcomes.10e16
Omalizumab results in a rapid reduction in free IgE levels and
correspondingly downregulates Fc3RI expression on baso-
phils and mast cells. These actions reduce IgE-mediated
responses to allergens, mast cell degranulation and release
of pro-inflammatory mediators.4,17e20 Omalizumab has also
been shown to reduce Fc3RI expression on antigen-present-
ing cells (dendritic cells [DCs]) prior to their trafficking into
tissues,21 suggesting that omalizumab may have the unique
capacity to block both sensitization and effector phases of
the allergic inflammatory process. There is evidence that
blocking IgE with omalizumab leads to an inhibitory effect on
eosinophils. Djukanovic´ et al.17 reported that omalizumab
monotherapy significantly reduced the number of sputum
and bronchial submucosal eosinophils in patients with
allergic asthma not receiving ICSs. This observed decrease in
sputum and bronchial submucosal eosinophils was accom-
panied by a reduction in submucosal IgEþ and Fc3RIþ cells.
The aim of this analysis was to assess the effect of
omalizumab on peripheral blood eosinophil counts in
patients with moderate-to-severe persistent allergic
asthma. In addition, the relationships between peripheral
blood eosinophils, serum free IgE concentrations and clin-
ical outcomes were explored.
Methods
Studies and patients
This pooled analysis included data from five randomized,
double-blind, placebo-controlled pivotal registration trials
that assessed efficacy and safety of omalizumab in the
treatment of patients with moderate-to-severe persistent
allergic asthma (Table 1).10e14 In all studies, patients were
12 years of age and were receiving ongoing therapy with
at least moderate-to-high doses of ICS at baseline.
A monthly dose of omalizumab of at least 0.016 mg/kg/IU
IgE was administered subcutaneously every 2 or 4 weeks,
according to a dosing table nomogram incorporating the
patient’s bodyweight and baseline IgE levels.
The treatment period in three studies consisted of two
phases: (1) a 16-week ‘steroid-stable’ phase during which
patients received omalizumab or placebo treatment inaddition to a fixed dose of ICS; and (2) a 12-week12,13 or
16-week14 ‘steroid-reduction’ phase. During the steroid-
reduction phase ICS doses were adjusted to provide the
lowest dose consistent with asthma control.12e14 Patients
who received omalizumab achieved median reductions in
ICS dose of 75%,22 83%23 and 60%14 compared with approx-
imately 50%12e14 in the placebo group (p< 0.01). Two
studies12,13 were also followed by extension phases that
were similar in design.22,23 Briefly, during the 24-week
double-blind extension phase, patients were maintained on
omalizumab or placebo and the lowest sustainable dose of
beclomethasone dipropionate (BDP). The use of other
asthma medications was permitted and investigators were
allowed to switch patients from BDP to other ICS medica-
tions. Full details of the five study designs have been
reported elsewhere.10e14
Circulating eosinophil counts and serum free
IgE concentrations
Blood sampleswere obtained at baseline and post-treatment
for measurement of the complete blood count (CBC)
including eosinophils. The CBC was analyzed using the Bayer
Advia 120 automated hematology system. Eosinophil counts
greater than 15%were confirmed bymanual differential. The
post-treatment (omalizumab or placebo) time point was
taken as the first available eosinophil laboratory evaluation
after (and including) Week 16. In the three steroid-reduction
studies,12e14 eosinophil counts were also calculated at the
end of the ‘steroid-reduction’ phase. In the two studies with
extension phases,22,23 change in eosinophil counts were
calculated at the end of the extension phase, taken as the
eosinophil laboratory evaluation at Week 52.
Blood samples were also collected for measurement of
serum total and free IgE at baseline and post-treatment.
Baseline pretreatment total IgE concentrations in serum
Table 2 Baseline demographic and clinical characteristics.
Omalizumab
(nZ 1136)
Placebo
(nZ 1100)
Age, years
Mean (SD) 40.5 (14.3) 40.2 (14.09)
Min, Max 12, 79 12, 74
Sex, n (%)
Males 476 (41.9) 458 (41.6)
Females 660 (58.1) 642 (58.4)
Baseline FEV1, n (%)
80% 313 (27.6) 305 (27.7)
60e79% 519 (45.7) 502 (45.6)
<60% 304 (26.8) 293 (26.6)
Serum total IgE (IU/mL),
mean (SD)
213 (169.3) 209.5 (163.88)
Total clinical symptoms
score, mean (SD)
5.9 (6.34) 5.8 (6.26)
Baseline ICS in BDP
equivalent (mg/day),
mean (SD)
1409 (1076) 1402 (1008.1)
Baseline oral
corticosteroid use, n (%)
Yes 99 (8.7) 87 (7.9)
No 1037 (91.3) 1013 (92.1)
Baseline LABA use, n (%)
Yes 376 (33.1) 349 (31.7)
No 760 (66.9) 751 (68.3)
BDPZ beclomethasone dipropionate; FEV1Z forced expiratory
190 M. Massanari et al.was determined by a microparticle enzyme immunoassay
test kit commercially available from Abbott Inc. Free IgE
was measured using a solid-phase ELISA, as described
previously.24
Eosinophil counts in subgroups of serum free IgE
levels<50 ng/mL and ‡50 ng/mL
For the studies from which IgE data were availa-
ble,10,12e14 changes from baseline to post-treatment in
mean eosinophil counts were grouped according to
patients who achieved suppression of free IgE levels to
<50 ng/mLd vs patients who had not (i.e. free IgE levels
50 ng/mL).
Eosinophil counts in subgroup of patients receiving
maintenance oral corticosteroids (OCS) at baseline
Changes from baseline to post-treatment in mean eosino-
phil counts were determined for those patients receiving
maintenance OCS at baseline.
Clinical outcomes
The clinical outcomes assessed were: (1) total number
of steroid bursts associated with treatment of asthma
exacerbations10,11; (2) investigator’s global evaluation
of treatment effectiveness (GETE) which was rated
as ‘excellent/good’, ‘moderate’, or ‘poor/worse’; and
(3) lung function assessed as change from baseline in forced
expiratory volume in 1 s (FEV1). The effect of omalizumab
on steroid bursts and GETE was determined at the end of
the ‘steroid-reduction’ phase12e14 or the end of the
study.10,11 A steroid burst was defined as a dose of oral
prednisone (40e60 mg) in single or two divided daily doses
for adults or 1e2 mg/kg/day (maximum 60 mg/day) for
patients less than 18 years, generally administered for
3e10 days. The last non-missing observation in the ‘steroid-
stable’ phase was considered the end of study FEV1
measurement for the three studies that had a ‘steroid-
reduction’ phase.12e14 The last non-missing observation
after the treatment phase was considered the end of study
FEV1 measurement for the remaining two studies.
10,11 The
relationships between changes in eosinophil counts and
clinical outcomes were explored.
Statistical methods
Absolute eosinophil counts at baseline and post-baseline
time points were summarized descriptively for the oma-
lizumab and placebo group and the mean change from
baseline calculated. T-tests were used to determine if
mean changes were different from zero for each treat-
ment group. The two-tailed null hypothesis stated that
the mean change from baseline to the post-baseline time
point in eosinophil counts was not different from zero. For
each post-baseline time point, change from baseline was
analyzed using an analysis of covariance (ANCOVA) modeld 2.44 ng/mLZ 1 IU.with baseline eosinophil value, age, gender, treatment
group (omalizumab or placebo), dosing schedule (every 2
or 4 weeks) and study centre as explanatory variables.
Least squares means (LSM) were computed for each
treatment group as well as 95% confidence intervals (CIs)
for LSM treatment differences and p-values for the
treatment difference. The number of asthma exacerba-
tions requiring steroid bursts was analyzed using Poisson
regression with treatment, age, gender, use of oral
steroids at baseline, baseline FEV1 (80%, 60e79%,
<60%), dosing schedule and study as explanatory vari-
ables.25,26 The relative risk (RR) for omalizumab versus
placebo was calculated and presented with corresponding
95% CI. Investigator-determined GETE were analyzed
using CochraneManteleHaenszel mean score test adjust-
ing for study.25 Change from baseline in FEV1 was
analyzed using ANCOVA with treatment, age, gender,
baseline FEV1, dosing schedule and study as explanatory
variables; LSM of the change from baseline and 95% CI
were calculated. All analyses were performed using SAS
Version 9.1 (Copyright ª 2002e2003 by SAS Institute Inc.,
Cary, NC, USA).volume in 1 s; ICSZ inhaled corticosteroids; IgEZ immunoglo-
bulin E; LABAZ long-acting b2-agonist; SDZ standard
deviation.
Table 3 Eosinophil counts (109/L) at baseline and post-
treatment (Week 16), change from baseline, and
percentage change from baseline in patients treated with
omalizumab or placebo.
Omalizumab Placebo
Baseline, mean
(SD)
0.321 (0.2399)
[nZ 1116]
0.332 (0.2504)
[nZ 1082]
Post-treatment,
mean (SD)
0.262 (0.2020)
[nZ 1084]
0.320 (0.2596)
[nZ 1033]
Change from
baseline,
mean (SD)
0.057 (0.2178) 0.012 (0.2497)
p-value* p< 0.0001
[nZ 1069]
pZ 0.1199
[nZ 1019]
Percentage
change from
baseline,
mean (SD)
3.961 (82.0639) 23.089 (179.4656)
Median
(min, max)
18.75
(100.00, 1218.68)
[nZ 1060]
2.097
(100.00, 4397.92)
[nZ 1016]
*Two-tailed t-test with the following null hypothesis: mean
change in eosinophil count from baseline to post-baseline time
point is not different from zero.
Table 4 Eosinophil counts (109/L) at baseline, Week 16
and Week 28 or 32, change from baseline, and percentage
change from baseline in patients treated with omalizumab
or placebo in three studies that included a steroid-reduc-
tion phase.12e14
Omalizumab Placebo
Baseline, mean
(SD)
0.316 (0.2502)
[nZ 701]
0.317 (0.2288)
[nZ 680]
End of the steroid-
stable phase,
mean (SD)
0.242 (0.1766)
[nZ 683]
0.301 (0.2216)
[nZ 645]
Change from
baseline, mean (SD)
0.069 (0.2244) 0.016 (0.2288)
p-value* p< 0.0001 pZ 0.0838
[nZ 669] [nZ 633]
Percentage
change from
baseline, mean
(SD), median
(min, max)
8.002 (66.4733),
21.238 (100.00,
660.36)
18.579 (193.3906),
3.667 (100.00,
4397.92)
[nZ 665] [nZ 631]
End of the
steroid-
0.266 (0.2090)
[nZ 657]
0.326 (0.2238)
[nZ 608]
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Baseline demographic and clinical characteristics
Data for 1136 omalizumab-treated patients and 1100
placebo recipients were analyzed. In the three studies that
included a steroid-reduction phase, data were available for
1412 patients (omalizumab: nZ 718; placebo: nZ 694). In
the two studies with an extension phase, data were avail-
able for 1071 patients (omalizumab: nZ 542; placebo:
nZ 529). The treatment groups were well matched in
terms of baseline demographic and clinical characteristics
(Table 2). Overall, approximately 96% of patients met GINA
2002 criteria for severe persistent asthma based on both
symptoms and asthma therapy.1Figure 1 Least squares mean (LSM) change from baseline to
post-baseline time point in eosinophil counts (all five studies).Eosinophil counts and free IgE levels
Mean eosinophil counts at baseline were similar in the two
treatment groups (Table 3). Post-treatment eosinophil
counts were significantly reduced from baseline in the
omalizumab group (p< 0.0001) but were not significantly
different in the placebo group. The LSM treatment differ-
ence for the post-treatment change from baseline in
eosinophil counts was 0.051 109/L in favour of omal-
izumab (p< 0.0001) (Fig. 1).
In the three studies that comprised ‘steroid-stable’ and
‘steroid-reduction’ phases,12e14 eosinophil counts were
significantly reduced from baseline in the omalizumab
group at the end of each phase (Table 4). There was no
significant change in the placebo group at either time point
(Table 4).reduction
phase, mean
(SD)
Change from
baseline,
mean (SD)
0.043 (0.2518) 0.010 (0.2262)
p-value* p< 0.0001 pZ 0.2718
[nZ 645] [nZ 597]
Percentage
change from
baseline,
mean (SD),
median
(min, max)
3.410 (89.0318),
14.583 (100.00,
860.87)
[nZ 641]
26.603 (111.3232),
3.589 (100.00,
1584.38)
[nZ 595]
*Two-tailed t-test with the following null hypothesis: mean
change in eosinophil count from baseline to post-baseline time
point is not different from zero.
Table 5 Eosinophil counts (109/L) at baseline, end of
steroid-reduction phase and end of study extension phase,
change from baseline in patients, and percentage change
from baseline treated with omalizumab or placebo in the
192 M. Massanari et al.The LSM treatment difference for the change from
baseline in eosinophil counts was 0.057 109/L in favour
of omalizumab (p< 0.0001) at the end of the ‘steroid-
stable’ phase (Fig. 2a) and 0.057 109/L in favour ofFigure 2 Least squares mean (LSM) change from baseline in
eosinophil counts at the end of the steroid-stable phase (Week
16) [a], and at the end of the steroid reduction phase (Week 28 or
32) in the three studies of this design [b]; and at the end of the
extension phase in the two studies with extension phases [c].
two studies with extension phase.12,13,22,23
Omalizumab Placebo
Baseline, mean (SD) 0.304 (0.1960)
[nZ 530]
0.325 (0.2179)
[nZ 520]
End of the steroid-
reduction phase,
mean (SD)
0.265 (0.2065)
[nZ 494]
0.329 (0.2056)
[nZ 450]
Change from
baseline, mean
(SD)
0.033 (0.2118) 0.006 (0.1973)
p-value* p< 0.001 pZ 0.512
[nZ 485] [nZ 442]
Percentage
change from
baseline, mean
(SD), median
(min, max)
3.480 (87.4590),
14.039,
(100.00,
860.87)
20.756 (102.7313),
2.349 (100.00,
1584.38)
End of the
extension phase,
mean (SD)
0.252 (0.1669)
[nZ 455]
0.310 (0.2062)
[nZ 396]
Change from
baseline,
mean (SD)
0.049 (0.1775) 0.010 (0.2017)
p-value* p< 0.001 pZ 0.318
[nZ 445] [nZ 392]
Percentage change
from baseline,
mean (SD),
median
(min, max)
1.440
(66.4215),
15.749,
(100.00,
520.23)
[nZ 444]
16.562 (91.4919),
0.142 (100.00,
1047.92)
[nZ 392]
*Two-tailed t-test with the following null hypothesis: mean
change in eosinophil count from baseline to post-baseline time
point is not different from zero.omalizumab (p< 0.0001) at the end of the ‘steroid-reduc-
tion’ phase (Fig. 2b).
In the two studies with extension phases,22,23 eosinophil
counts were significantly reduced from baseline in the oma-
lizumab group at the end of the extension phase (Table 5).
Changes from baseline in the placebo group were not
significant (Table 5). The LSM treatment difference for the
change from baseline in eosinophil counts at the end of the
extension phasewas0.048 109/L in favour of omalizumab
(p< 0.001; Fig. 2c).
Eosinophil counts in subgroups of serum free IgE
levels<50 ng/mL and ‡50 ng/mL
Patients with post-treatment free IgE levels <50 ng/mL
(nZ 786) achieved a mean (SD) change in eosinophil counts
Table 7 Clinical outcomes in patients treated with oma-
lizumab or placebo. Data are presented as percent of
patients.
Outcome Omalizumab Placebo
nZ 1069 nZ 1019
Exacerbations
No steroid burst and
decrease in PBE
48.5 34.2
Steroid burst use and
increase in PBE
9.0 17.6
Investigator GETE
Positive GETE and
decrease in PBE
40.5 19.1
Negative GETE and
increase in PBE
4.8 14.6
Pulmonary function
FEV1 increase and
decrease in PBE
43.6 30.0
FEV1 decrease and
increase in PBE
15.4 26.4
GETE: global evaluation of treatment effectiveness; PBE:
peripheral blood eosinophil.
Effect of omalizumab on eosinophilia in allergic asthma 193(109/L) from baseline to post-baseline time point of 0.059
(0.2218) 109/L (omalizumab: nZ 753, 0.062 [0.2254];
placebo: nZ 33, 0.000 [0.0955] 109/L). In contrast,
patients with post-treatment free IgE levels 50 ng/mL
(nZ 718) had a lesser change in eosinophil counts (109/L)
from baseline to post-baseline time point of 0.008
(0.2560) 109/L (omalizumab: nZ 25, 0.065 [0.1328);
placebo: nZ 693, 0.006 [0.2592) 109/L).
Eosinophil counts in patients receiving
maintenance OCS at baseline
Omalizumab patients who were also receiving maintenance
OCS at baseline (nZ 88) achieved a mean (SD) decrease in
eosinophil count (109/L) from baseline to post-baseline
time point of 0.010 (0.2470) 109/L, compared with
patients receiving placebo (nZ 84) who experienced
a mean (SD) increase of 0.034 (0.2654) 109/L.
Clinical outcomes
The mean number of asthma exacerbations requiring
treatment with steroid bursts was lower in the omalizumab
group compared with placebo (Table 6). The mean (SD)
number of steroid bursts was 0.4 (0.87) and 0.6 (1.23) for
omalizumab and placebo, respectively. The relative risk for
omalizumab to placebo was 0.66 (95% CI: 0.56, 0.77); thus,
it would be expected that an omalizumab-treated patient
would require 34% fewer steroid bursts than those receiving
placebo (p< 0.001).
LSM change from baseline in FEV1 was improved in the
omalizumab group compared with placebo (LSM treatment
difference [95% CI] 75.12 [44.41, 105.84], p< 0.0001;Table 6 Clinical outcomes in patients treated with oma-
lizumab or placebo.
Omalizumab Placebo
nZ 1136 nZ 1100
Mean number
of steroid bursts
0.4 0.6
RR versus placebo (95%
CI)
0.66 (0.56, 0.77)
p value for RR p< 0.001
Mean (%) change from
baseline in FEV1, mL
111.5 (6.1%) 30.7 (2.5%)
LSM 116.19 41.07
LSM treatment
difference (95% CI)
75.12 (44.41, 105.84)
p value p< 0.0001
Investigator GETE, n (%)
Excellent/good 665 (58.5) 406 (36.9)
Moderate 283 (24.9) 312 (28.4)
Poor/worse 137 (12.1) 332 (30.2)
p value p< 0.001
RR: relative risk; LSM: least mean squares GETE: global evalu-
ation of treatment effectiveness.Table 6). Investigator-determined GETE showed significant
improvements in favour of omalizumab. Physicians rated
treatment effectiveness as ‘excellent’ or ‘good’ in 59% of
omalizumab-treated patients compared with 37% in the
placebo group (p< 0.001; Table 6).
In general, a greater percentage of patients receiving
omalizumab experienced an improvement in clinical
outcomes and a decrease in eosinophil counts (Table 7).
Discussion
Findings from this pooled analysis demonstrate that
reduction of serum free IgE by omalizumab is associated
with a significant reduction in peripheral eosinophil counts
in patients with moderate-to-severe persistent allergic
asthma receiving moderate-to-high doses of ICS. In the
pooled analysis of 5 studies, circulating eosinophils were
reduced by a median of 18.8% and 2.1% in the omalizumab
and placebo groups, respectively (Table 3). In the three
studies that included a ‘steroid-reduction’ phase, reduc-
tions in eosinophil counts were maintained despite
a significant reduction in ICS dose to levels that are less
likely to be associated with systemic activity e circulating
eosinophils were reduced in the omalizumab group by
a median of 21.2% at the end of the ‘steroid-stable’ phase
and a median of 14.6% at the end of the ‘steroid-reduc-
tion’ phase (at the same time points, eosinophil counts in
the placebo group were decreased by a median of 3.7%
and increased by 3.6%, respectively; Tables 4 and 5).
In two studies, patients entered a long-term extension
following the ‘steroid-reduction’ phase. During the exten-
sion phase, omalizumab sustained the decrease in eosino-
phil counts observed following steroid reduction. These
reductions in eosinophil counts following treatment with
194 M. Massanari et al.omalizumab were accompanied by improvements in a range
of clinical outcome measures.
The significant reduction in eosinophil counts observed
in our pooled analysis adds evidence from a large patient
population to that obtained from smaller studies, which
reported an inhibitory effect of omalizumab on eosinophils.
In one study of 35 patients with moderate-to-severe allergic
asthma, omalizumab significantly decreased circulating
eosinophils at both 16 and 52 weeks (p< 0.01 vs placebo).27
Evidence of attenuation of eosinophil infiltration into the
lungs was provided by Djukanovic´ and colleagues in a study
of 45 patients with corticosteroid-naive, mild-to-moderate
persistent allergic asthma who underwent bronchial biopsy
and induced-sputum sampling.17 In the omalizumab group,
the percentage of eosinophils present in induced sputum
decreased from 4.8% to 0.6% (pZ 0.05 vs placebo) and
tissue eosinophils in the bronchial submucosa were signifi-
cantly reduced from 8.0 to 1.5 cells/mm2 (pZ 0.03 vs
placebo).
In a study of 19 patients with coexisting allergic asthma
and rhinitis, omalizumab therapy induced eosinophil
apoptosis and reduced the number of lymphocytes
producing GM-CSF, an important factor for eosinophil
growth and survival.28 Furthermore, a study of 30 adults
with seasonal allergic rhinitis reported that blood eosino-
phils increased significantly in the placebo group, remained
unchanged in the omalizumab group, and that differences
between treatment groups were statistically significant.29
The authors also reported that seasonal increases and
inhibitory effects of treatment were mirrored in the
changes in eosinophils (staining positively for eosinophil
peroxidase) in nasal biopsy specimens. Moreover, the
number of nasal tissue eosinophils correlated significantly
with serum free IgE levels.
Despite having established a considerable evidence base
supporting the effects of omalizumab on circulating and
bronchial eosinophils, the mechanism whereby reductions
in circulating IgE can ultimately lead to a reduction in
eosinophils remains unclear. It is possible that omalizumab
may lead to inhibition of the release of pro-inflammatory
mediators, cytokines and chemokines from mast cells/
basophils, or inhibition of the allergen-induced differenti-
ation of T-cells to Th2 cells by markedly reducing the
expression of Fc3RI on these cells. The mediators of
greatest interest are the Th2 cytokines IL-4, IL-5 and IL-13
as these are responsible for promoting recruitment and
activation of mast cells and eosinophils and are the primary
effector cells of the allergic response.30 It is known that
IL-4, IL-5 and IL-13 levels are increased in the sera of
patients with asthma.31 Moreover, IL-4 and IL-13 play
a central role in promoting eosinophil trafficking, as well as
driving Th2 cell differentiation, whereas IL-5 is the major
cytokine promoting eosinophil differentiation, proliferation
and activation.3
Omalizumab has been shown to significantly reduce IL-4
positive cells in the bronchial submucosa and reduce IL-5
positive cells, although this latter reduction was not
statistically significant.17 A significant reduction in circu-
lating IL-13 and a non-significant reduction in circulating
IL-5 have also been reported with omalizumab in patients
with moderate-to-severe allergic asthma.27 Eosinophil
apoptosis and reduced numbers of lymphocytes producingGM-CSF have been observed in omalizumab-treated
patients with coexisting allergic asthma and rhinitis, which
may also contribute to the inhibitory action of omalizumab
on eosinophils.28
A direct effect of omalizumab on eosinophils may be
possible via the Fc3RI receptors that have been detected on
eosinophils; however, their functional significance has yet
to be established.32,33 Studies examining blood from atopic
subjects have detected only negligible surface expression
of functional Fc3RI on eosinophils; however, appreciable
intracellular staining for Fc3RI was observed.33,34 Of note,
cross-linking of the surface- expressed receptors did not
lead to any detectable degranulation response.33,34
Furthermore, a study that sampled eosinophils from trans-
genic mice found that IL-10 was secreted after Fc3RI acti-
vation, suggesting some contribution to the regulation of
the immune response.35
The anti-eosinophilic effects of ICS are well doc-
umented36e38 but it is noteworthy that the significant
reductions seen with add-on omalizumab in this analysis
were achieved in study populations that were already
receiving ICS. Leukotriene modifiers have also demon-
strated anti-eosinophilic effects but these were of a smaller
magnitude than that achieved using ICS.39 Of note, it has
been reported that the leukotriene receptor antagonist
montelukast failed to reduce sputum eosinophilia in
patients with high-dose corticosteroid-dependent
asthma.40
In our analysis, a greater proportion of patients
receiving omalizumab experienced improvement in clinical
outcomes (reduced requirement for treatment of exacer-
bations with oral steroid bursts, increased FEV1, and
positive investigator GETE) and a decrease in peripheral
blood eosinophils compared to those receiving placebo. A
consistent pattern of improved clinical outcomes/
decreased eosinophils and worsened clinical outcomes/
increased eosinophils was observed for both omalizumab
and placebo treatment groups. However, the clinical
significance of the decrease in peripheral blood eosino-
phils, and in particular how this is related to improvements
in FEV1 and GETE, is uncertain. Weak associations, as
measured by Pearson and Spearman correlation coeffi-
cients, were observed between change (decrease) from
baseline in eosinophil counts and various clinical variables
(data not shown).
In summary, our findings from this pooled analysis of five
large randomized controlled studies in patients with
moderate-to-severe or severe persistent allergic asthma
expand the understanding of the mechanism of action of
omalizumab beyond binding of serum IgE to include effects
on the marker of inflammation, peripheral blood
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